CATX Perspective Therapeutics | $1.60 +4.6% | 5/6/2024 | Reiterated by | Lifesci Capital | Analyst A. Dhankher | Outperform | | N/A | View details for Lifesci Capital rating of Perspective Therapeutics (NYSE:CATX) on 5/6/2024 |
CATX Perspective Therapeutics | $1.60 +4.6% | 5/6/2024 | Reiterated by | Lifesci Capital | Analyst A. Dhankher | Outperform | | N/A | View details for Lifesci Capital rating of Perspective Therapeutics (NYSE:CATX) on 5/6/2024 |
MLYS Mineralys Therapeutics | $13.00 -1.1% | 3/26/2024 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Mineralys Therapeutics (NASDAQ:MLYS) on 3/26/2024 |
GPCR Structure Therapeutics | $36.15 +0.8% | 2/27/2024 | Reiterated by | Lifesci Capital | Analyst M. Belghiti | Outperform | | Low | View details for Lifesci Capital rating of Structure Therapeutics (NASDAQ:GPCR) on 2/27/2024 |
VTYX Ventyx Biosciences | $4.73 -5.0% | 2/28/2024 | Upgraded by | Lifesci Capital | Analyst S. Slutsky | Market Perform -> Outperform | | Low | View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 2/28/2024 |
LRMR Larimar Therapeutics | $7.38 -0.7% | 2/20/2024 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/20/2024 |
The Overlooked Retirement Asset You Probably Don’t Own (Ad) 4 out of 5 Americans believe we’re on the brink of a retirement crisis.
Luckily, in these unprecedented times, we have an unprecedented solution.
Once considered a “fringe” investment, the crypto market is now taking the world by storm. Click here to access the Crypto Retirement Blueprint now. |
INBX Inhibrx | $34.70 +0.6% | 1/23/2024 | Downgraded by | Lifesci Capital | Analyst S. Slutsky | Outperform -> Market Perform | | Low | View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 1/23/2024 |
IVA Inventiva | $3.79 +3.8% | 1/5/2024 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Inventiva (NASDAQ:IVA) on 1/5/2024 |
TARS Tarsus Pharmaceuticals | $38.24 -0.9% | 12/26/2023 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 12/26/2023 |
RCKT Rocket Pharmaceuticals | $22.62 -3.3% | 12/26/2023 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/26/2023 |
SYRE Spyre Therapeutics | $37.80
| 12/4/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Spyre Therapeutics (NASDAQ:SYRE) on 12/4/2023 |
TCRX TScan Therapeutics | $8.98 +0.9% | 11/27/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of TScan Therapeutics (NASDAQ:TCRX) on 11/27/2023 |
VTYX Ventyx Biosciences | $4.73 -5.0% | 11/7/2023 | Downgraded by | Lifesci Capital | Analyst S. Slutsky | Outperform -> Market Perform | | Low | View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 11/7/2023 |
VERV Verve Therapeutics | $5.98 -6.3% | 8/8/2023 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Verve Therapeutics (NASDAQ:VERV) on 8/8/2023 |
INBX Inhibrx | $34.70 +0.6% | 8/8/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 8/8/2023 |
TNYA Tenaya Therapeutics | $4.66 +9.6% | 8/8/2023 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 8/8/2023 |
PYXS Pyxis Oncology | $4.15 -0.5% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 4/26/2023 |
OLMA Olema Pharmaceuticals | $9.84 +1.9% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Olema Pharmaceuticals (NASDAQ:OLMA) on 4/26/2023 |
INBX Inhibrx | $34.70 +0.6% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 4/26/2023 |
AVDL Avadel Pharmaceuticals | $15.49 -2.8% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 4/26/2023 |
ALXO ALX Oncology | $14.21 -3.1% | 4/26/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 4/26/2023 |
IRON Disc Medicine | $32.18 +0.8% | 4/24/2023 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Disc Medicine (NASDAQ:IRON) on 4/24/2023 |
AKRO Akero Therapeutics | $19.92 -3.9% | 4/11/2023 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Akero Therapeutics (NASDAQ:AKRO) on 4/11/2023 |
IFRX InflaRx | $1.63 +12.4% | 4/5/2023 | Upgraded by | Lifesci Capital | - | Market Perform -> Outperform | | Low | View details for Lifesci Capital rating of InflaRx (NASDAQ:IFRX) on 4/5/2023 |
CRNX Crinetics Pharmaceuticals | $51.40 -1.0% | 3/27/2023 | Reiterated by | Lifesci Capital | Analyst C. Jubinville | Outperform | | Low | View details for Lifesci Capital rating of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 3/27/2023 |
OBIO Orchestra BioMed | $5.21 +12.8% | 3/8/2023 | Reiterated by | Lifesci Capital | Analyst R. Rakhit | Outperform | | Low | View details for Lifesci Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 3/8/2023 |
ELVN Enliven Therapeutics | $23.04 -3.2% | 3/7/2023 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Enliven Therapeutics (NASDAQ:ELVN) on 3/7/2023 |
MLTX MoonLake Immunotherapeutics | $39.75 -2.7% | 12/21/2022 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | N/A | View details for Lifesci Capital rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 12/21/2022 |
PYXS Pyxis Oncology | $4.15 -0.5% | 12/1/2022 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Low | View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 12/1/2022 |
ATXS Astria Therapeutics | $9.54 +1.2% | 11/28/2022 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Astria Therapeutics (NASDAQ:ATXS) on 11/28/2022 |
ALXO ALX Oncology | $14.21 -3.1% | 11/8/2022 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Low | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 11/8/2022 |
AKLI Akili | $0.43 -2.3% | 9/6/2022 | Reiterated by | Lifesci Capital | Analyst R. Rakhit | Outperform | | Low | View details for Lifesci Capital rating of Akili (NASDAQ:AKLI) on 9/6/2022 |
VYNE VYNE Therapeutics | $2.77 +2.6% | 8/12/2022 | Downgraded by | Lifesci Capital | Analyst P. Dolezal | Outperform -> Market Perform | | Low | View details for Lifesci Capital rating of VYNE Therapeutics (NASDAQ:VYNE) on 8/12/2022 |
LRMR Larimar Therapeutics | $7.38 -0.7% | 8/12/2022 | Upgraded by | Lifesci Capital | Analyst P. Dolezal | Market Perform -> Outperform | | Low | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 8/12/2022 |
TNYA Tenaya Therapeutics | $4.66 +9.6% | 6/16/2022 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 6/16/2022 |
VERA Vera Therapeutics | $41.39 -1.3% | 3/28/2022 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Vera Therapeutics (NASDAQ:VERA) on 3/28/2022 |
ELDN Eledon Pharmaceuticals | $3.02 +7.9% | 3/25/2022 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Medium | View details for Lifesci Capital rating of Eledon Pharmaceuticals (NASDAQ:ELDN) on 3/25/2022 |
LRMR Larimar Therapeutics | $7.38 -0.7% | 2/16/2022 | Downgraded by | Lifesci Capital | Analyst Patrick Dolezal | Outperform -> Market Perform | $3.00 | Medium | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/16/2022 |
VERV Verve Therapeutics | $5.98 -6.3% | 12/22/2021 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | High | View details for Lifesci Capital rating of Verve Therapeutics (NASDAQ:VERV) on 12/22/2021 |
ALLK Allakos | $1.44 -0.7% | 12/22/2021 | Downgraded by | Lifesci Capital | Analyst S. Slutsky | Outperform -> Market Perform | | High | View details for Lifesci Capital rating of Allakos (NASDAQ:ALLK) on 12/22/2021 |
Don’t expose yourself to stocks during the week (Ad) The S&P 500 just crossed below the 200 day moving average…
The Nasdaq is bleeding out… Are we headed for a recession?!
If you’ve been in the stock market the last few months, it hasn’t been fun…
But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend?
When the markets are closed. And volatility is minimal. Click here and I’ll give you all the details. |
NNOX Nano-X Imaging | $9.80 -0.3% | 11/17/2021 | Downgraded by | Lifesci Capital | Analyst R. Rakhit | Outperform -> Market Perform | | Low | View details for Lifesci Capital rating of Nano-X Imaging (NASDAQ:NNOX) on 11/17/2021 |
VTYX Ventyx Biosciences | $4.73 -5.0% | 11/15/2021 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | High | View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 11/15/2021 |
ALXO ALX Oncology | $14.21 -3.1% | 11/4/2021 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Medium | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 11/4/2021 |
PYXS Pyxis Oncology | $4.15 -0.5% | 11/2/2021 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Low | View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 11/2/2021 |
RCKT Rocket Pharmaceuticals | $22.62 -3.3% | 10/24/2021 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/24/2021 |
DRIO DarioHealth | $1.90 +1.1% | 8/26/2021 | Reiterated by | Lifesci Capital | Analyst R. Rakhit | Outperform | | High | View details for Lifesci Capital rating of DarioHealth (NASDAQ:DRIO) on 8/26/2021 |
VRDN Viridian Therapeutics | $13.45 -8.1% | 8/24/2021 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | Low | View details for Lifesci Capital rating of Viridian Therapeutics (NASDAQ:VRDN) on 8/24/2021 |
LRMR Larimar Therapeutics | $7.38 -0.7% | 8/4/2021 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Medium | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 8/4/2021 |
OLMA Olema Pharmaceuticals | $9.84 +1.9% | 6/21/2021 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | High | View details for Lifesci Capital rating of Olema Pharmaceuticals (NASDAQ:OLMA) on 6/21/2021 |
NNOX Nano-X Imaging | $9.80 -0.3% | 6/3/2021 | Reiterated by | Lifesci Capital | Analyst R. Rakhit | Outperform | | High | View details for Lifesci Capital rating of Nano-X Imaging (NASDAQ:NNOX) on 6/3/2021 |
ADVM Adverum Biotechnologies | $8.04 -2.5% | 4/29/2021 | Downgraded by | Lifesci Capital | Analyst P. Dolezal | Outperform -> Market Perform | | High | View details for Lifesci Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 4/29/2021 |
ELDN Eledon Pharmaceuticals | $3.02 +7.9% | 3/18/2021 | Reiterated by | Lifesci Capital | Analyst R. Katkhuda | Outperform | | High | View details for Lifesci Capital rating of Eledon Pharmaceuticals (NASDAQ:ELDN) on 3/18/2021 |
COGT Cogent Biosciences | $7.44 -0.4% | 1/4/2021 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | N/A | View details for Lifesci Capital rating of Cogent Biosciences (NASDAQ:COGT) on 1/4/2021 |
CLDX Celldex Therapeutics | $38.21 -4.3% | 11/17/2020 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | High | View details for Lifesci Capital rating of Celldex Therapeutics (NASDAQ:CLDX) on 11/17/2020 |
TARS Tarsus Pharmaceuticals | $38.24 -0.9% | 11/10/2020 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Medium | View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 11/10/2020 |
AVDL Avadel Pharmaceuticals | $15.49 -2.8% | 11/9/2020 | Reiterated by | Lifesci Capital | Analyst D. Sherman | Outperform | | Low | View details for Lifesci Capital rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 11/9/2020 |
ADVM Adverum Biotechnologies | $8.04 -2.5% | 11/5/2020 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Medium | View details for Lifesci Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 11/5/2020 |
IFRX InflaRx | $1.63 +12.4% | 10/30/2020 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Market Perform | | Low | View details for Lifesci Capital rating of InflaRx (NASDAQ:IFRX) on 10/30/2020 |
ALLK Allakos | $1.44 -0.7% | 10/22/2020 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | Low | View details for Lifesci Capital rating of Allakos (NASDAQ:ALLK) on 10/22/2020 |
MEIP MEI Pharma | $3.15 +7.5% | 10/21/2020 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Medium | View details for Lifesci Capital rating of MEI Pharma (NASDAQ:MEIP) on 10/21/2020 |
RCKT Rocket Pharmaceuticals | $22.62 -3.3% | 10/16/2020 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | Low | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/16/2020 |
INBX Inhibrx | $34.70 +0.6% | 10/15/2020 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Medium | View details for Lifesci Capital rating of Inhibrx (NASDAQ:INBX) on 10/15/2020 |
IMVT Immunovant | $30.70 -2.5% | 10/6/2020 | Reiterated by | Lifesci Capital | Analyst S. Slutsky | Outperform | | High | View details for Lifesci Capital rating of Immunovant (NASDAQ:IMVT) on 10/6/2020 |
VYNE VYNE Therapeutics | $2.77 +2.6% | 10/2/2020 | Reiterated by | Lifesci Capital | Analyst P. Dolezal | Outperform | | High | View details for Lifesci Capital rating of VYNE Therapeutics (NASDAQ:VYNE) on 10/2/2020 |
ALXO ALX Oncology | $14.21 -3.1% | 9/30/2020 | Reiterated by | Lifesci Capital | Analyst A. Evertts | Outperform | | Low | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 9/30/2020 |
CRTX Cortexyme | $0.91 -1.1% | 9/24/2020 | Reiterated by | Lifesci Capital | Analyst D. Sherman | Outperform | | High | View details for Lifesci Capital rating of Cortexyme (NASDAQ:CRTX) on 9/24/2020 |